Fasenra Approved for New Use in India

  Published 1 year ago

AstraZeneca’s Fasenra (Benralizumab) has received Indian regulatory approval for an additional indication: treating adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Marketing is pending further statutory approvals.

  • Fasenra gets expanded use in India.
  • Treats EGPA in adult patients.
  • Approval from Indian regulators.

You might like these

Govt to Buy Back Bonds Worth ₹30,000 Cr

India Stocks Dip Amid Middle East Tensions, Fed Watch

Mumbai Airport Payment Dispute: Airlines Push Back

Meta Appoints Arun Srinivas as India Managing Director

Welspun Q1 Revenue Jumps 24%

MobiKwik Stock Surges 15% on Supply Relief

Tata Sons Pumps $400M Into Digital

News that matters the most ⚡